section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension, QT interval prolongation, TORSADES DE POINTES

Derm: skin discoloration

EENT: blurred vision, dry eyes

Endo: galactorrhea (women)

GI: constipation, dry mouth, ↓appetite, nausea, vomiting, weight loss

GU: ↓libido, erectile dysfunction

Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia

Neuro: akinesia, drowsiness, parkinsonism, akathisia, dystonic reactions, mood/behavior effects, NEUROLEPTIC MALIGNANT SYNDROME, tardive dyskinesia, weakness

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Drug-Food:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Action ⬆ ⬇

  • Blocks dopamine receptors in the CNS.
  • Increases brain turnover of dopamine, blocks calcium channels, and may antagonize opiate receptors.
Therapeutic effects:
  • Decreased tics in patients with Tourette’s disorder.

Classifications ⬆ ⬇

Therapeutic Classification: antipsychotics

Pharmacokinetics ⬆ ⬇

Absorption: 50% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Undergoes extensive first-pass hepatic metabolism, primarily by the CYP3A4 isoenzyme and to a lesser extent by the CYP1A2 and CYP2D6 isoenzymes; the CYP2D6 isoenzyme exhibits genetic polymorphism (∼7% of population may be poor metabolizers [PMs] and may have significantly ↑ pimozide concentrations and an ↑ risk of adverse effects). Some metabolites have CNS activity.

Half-Life: 29–111 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown6–8 hrunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

PI-mo-zide

Code ⬆

NDC Code